Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMY4UMW)

Drug Name
Atovaquone Drug Info
Synonyms
Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ
Therapeutic ClassAntifungal Agents
Cross-matching ID
PubChem CID
74989
ChEBI ID
CHEMBL575568
CAS Number
CAS 94015-53-9
TTD Drug ID
D06ZEE
INTEDE Drug ID
DR0158
ACDINA Drug ID
D00849

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 2.22 0.00e+0 48/60 (80%) MT1X;MT1F;MT1H;...
Drug metabolism 2.02 0.00e+0 78/151 (51.66%) FMO1;MPO;ALDH3A1;...
IL-17 signaling pathway 2.00 0.00e+0 84/94 (89.36%) LCN2;CXCL3;CXCL2;...
Glycolysis / Gluconeogenesis 1.94 2.19e-3 56/67 (83.58%) DLD;PCK1;GPI;...
Pentose and glucuronate interconversions 1.91 3.50e-3 17/34 (50%) SORD;DCXR;UGP2;...
Citrate cycle (TCA cycle) 1.89 4.37e-3 30/30 (100%) DLD;PCK1;IDH2;...
Pentose phosphate pathway 1.86 8.74e-3 25/30 (83.33%) GPI;ALDOB;PFKL;...
Metabolism of xenobiotics by cytochrome P450 1.86 7.65e-3 49/77 (63.64%) HSD11B1;CBR3;AKR7A2;...
Tryptophan metabolism 1.86 7.77e-3 35/42 (83.33%) DLD;AOC1;ECHS1;...
Thiamine metabolism 1.84 7.87e-3 12/15 (80%) AK4;AK1;ALPL;...
Glyoxylate and dicarboxylate metabolism 1.84 7.15e-3 23/30 (76.67%) DLD;ACO1;ACAT2;...
Glutathione metabolism 1.82 8.01e-3 43/57 (75.44%) ANPEP;IDH2;GPX3;...
Pyruvate metabolism 1.82 7.40e-3 41/47 (87.23%) DLD;PCK1;LDHB;...
TNF signaling pathway 1.80 9.37e-3 103/112 (91.96%) CXCL3;CXCL2;CXCL1;...
Propanoate metabolism 1.80 8.74e-3 30/34 (88.24%) DLD;ALDH6A1;ECHS1;...
Arginine and proline metabolism 1.79 8.74e-3 39/50 (78%) AOC1;ARG1;CKB;...
Fructose and mannose metabolism 1.79 8.23e-3 30/33 (90.91%) SORD;ALDOB;GMDS;...
Galactose metabolism 1.75 1.26e-2 26/31 (83.87%) PFKL;MGAM;PFKP;...
Glycine, serine and threonine metabolism 1.73 1.52e-2 31/40 (77.5%) DLD;BPGM;BHMT;...
Lysine degradation 1.72 1.49e-2 51/63 (80.95%) DLD;ECHS1;ACAT2;...
Epithelial cell signaling in Helicobacter pylori infect... 1.70 1.96e-2 62/70 (88.57%) CXCL3;CXCL2;CXCL8;...
NF-kappa B signaling pathway 1.68 2.34e-2 90/104 (86.54%) CXCL3;CXCL2;CXCL8;...
Non-alcoholic fatty liver disease 1.65 3.04e-2 126/155 (81.29%) CXCL8;FOS;NDUFS7;...
Valine, leucine and isoleucine degradation 1.64 3.35e-2 42/48 (87.5%) DLD;ALDH6A1;ECHS1;...
beta-Alanine metabolism 1.63 3.74e-2 25/30 (83.33%) ALDH6A1;ECHS1;ALDH3A1;...
DNA replication 1.60 4.24e-2 34/36 (94.44%) RPA3;MCM5;MCM6;...
Glycerolipid metabolism 1.60 4.21e-2 44/61 (72.13%) PLPP3;MBOAT2;LPL;...
Oxidative phosphorylation 1.60 4.06e-2 93/133 (69.92%) NDUFS7;COX4I1;ATP6V1D;...
Mismatch repair 1.59 4.28e-2 22/23 (95.65%) RPA3;PCNA;POLD1;...
Gap junction -1.64 4.72e-2 72/88 (81.82%) GNAQ;HTR2B;LPAR1;...
Antigen processing and presentation -1.65 4.72e-2 60/78 (76.92%) HSPA5;HLA-C;RFX5;...
Systemic lupus erythematosus -1.67 4.05e-2 45/135 (33.33%) FCGR2A;HLA-DQB1;CD86;...
Cell adhesion molecules -1.69 3.03e-2 118/148 (79.73%) HLA-F;ITGB8;CLDN4;...
Arrhythmogenic right ventricular cardiomyopathy -1.69 3.00e-2 70/77 (90.91%) DSG2;ATP2A3;CACNG2;...
Autoimmune thyroid disease -1.71 2.86e-2 46/53 (86.79%) HLA-F;TSHR;HLA-DQB1;...
Intestinal immune network for IgA production -1.71 2.81e-2 38/48 (79.17%) HLA-DQB1;CD86;HLA-DPB1;...
Cortisol synthesis and secretion -1.77 1.26e-2 58/65 (89.23%) HSD3B2;SP1;CACNA1S;...
Dilated cardiomyopathy -1.77 1.15e-2 86/96 (89.58%) ATP2A3;CACNG2;SGCA;...
Type I diabetes mellitus -1.80 1.29e-2 38/43 (88.37%) HLA-C;GAD1;IL1B;...
Leishmaniasis -1.80 1.47e-2 67/77 (87.01%) CR1;TGFB2;JAK1;...
Graft-versus-host disease -1.82 1.53e-2 32/42 (76.19%) IL1B;HLA-F;HLA-DQB1;...
Allograft rejection -1.85 1.15e-2 32/38 (84.21%) HLA-F;HLA-DQB1;HLA-B;...
Cushing syndrome -1.87 1.43e-2 125/155 (80.65%) CAMK2B;HSD3B2;SP1;...
Platelet activation -1.89 1.53e-2 106/124 (85.48%) VWF;P2RX1;PLCB3;...
Phagosome -1.95 1.15e-2 118/152 (77.63%) DYNC1H1;MBL2;ITGAM;...
Viral myocarditis -1.96 2.29e-2 53/60 (88.33%) SGCB;HLA-C;MYH7;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H